CN111304134A - 一株能有效缓解糖尿病的植物乳杆菌 - Google Patents
一株能有效缓解糖尿病的植物乳杆菌 Download PDFInfo
- Publication number
- CN111304134A CN111304134A CN202010223696.XA CN202010223696A CN111304134A CN 111304134 A CN111304134 A CN 111304134A CN 202010223696 A CN202010223696 A CN 202010223696A CN 111304134 A CN111304134 A CN 111304134A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- group
- diabetes
- strain
- normal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 24
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 24
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 24
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 22
- 238000009629 microbiological culture Methods 0.000 claims abstract description 4
- 238000004321 preservation Methods 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000008280 blood Substances 0.000 abstract description 24
- 210000004369 blood Anatomy 0.000 abstract description 24
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 11
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- 239000008103 glucose Substances 0.000 description 14
- 239000006041 probiotic Substances 0.000 description 14
- 235000018291 probiotics Nutrition 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 230000000529 probiotic effect Effects 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 3
- 238000007446 glucose tolerance test Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 102000004366 Glucosidases Human genes 0.000 description 2
- 108010056771 Glucosidases Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- -1 diamine citrate Chemical class 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 108091005995 glycated hemoglobin Proteins 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明提供一株能有效缓解糖尿病的植物乳杆菌(Lactobacillus plantarum)AR113菌株,该植物乳杆菌AR113菌株已在2017年3月22日保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为CGMCC No.13909。本发明的植物乳杆菌AR113菌株能够有效缓解甚至治疗糖尿病,能够起到降低血糖和改善胰岛素抵抗的作用。
Description
技术领域
本发明属于微生物领域,具体涉及一株能有效缓解糖尿病的植物乳杆菌。
背景技术
糖尿病是一类严重的慢性疾病,其致病原理是由于在人体内无法产生足够的胰岛素或者细胞无法有效的使用其产生的胰岛素。典型的症状是血糖浓度过高,主要分为3大类包括:Ⅰ型,Ⅱ型,妊娠型。其中II型糖尿病是最常见的类型,占糖尿病患者的90%以上,甚至会引发冠心病、动脉粥样硬化、肾脏病变、神经病变、视网膜病变以及足部病变等并发症。目前针对糖尿病治疗有两种方法:一种是注射胰岛素治疗,但有可能会造成胰岛素抵抗;第二种是口服降血糖药物,但是长期服用药物会引起一些副作用,如腹泻、头晕、恶心、食欲不振、低血糖和肝功能损伤等,严重影响患者的身体健康。急需一种安全、无毒副作用的缓解甚至治疗糖尿病的方法,近年来,益生菌的益生功能引起了人们的广泛关注。益生菌,指主要定植于人体肠道和生殖系统内,能产生确切健康功效从而改善宿主微生态平衡、发挥有益作用的具有活性的微生物的总称。益生菌具有低成本、高安全性和高可靠性的特点。
发明内容
本发明是为了解决上述问题而进行的,目的在于提供一株能有效缓解糖尿病的植物乳杆菌。
本发明提供了一种能有效缓解糖尿病的植物乳杆菌(Lactobacillusplantarum)AR113菌株,具有这样的特征,所述植物乳杆菌AR113菌株已在2017年3月22日保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为CGMCC No.13909。
本发明还提供了利用植物乳杆菌AR113菌株制备用于缓解糖尿病的制品中的应用。
发明的作用与效果
根据本发明所涉及的能有效缓解糖尿病的植物乳杆菌,该植物乳杆菌是安全、无毒副作用的益生菌,能够有效缓解甚至治疗糖尿病,即降低血糖的同时还能改善胰岛素抵抗,另外,还具有可以长期实用的安全性,且成本低、安全性高、可靠性高,能够用来制备用于缓解甚至治疗糖尿病的药品、保健品或食品饮品。
附图说明
图1是本发明的实施例中各处理组小鼠体重变化图;
图2是本发明的实施例中正常小鼠喂食益生菌后血糖变化图;
图3是本发明的实施例中模型小鼠喂食益生菌后血糖变化图;
图4是本发明的实施例中模型小鼠喂食益生菌后葡萄糖耐受实验后的血糖变化图;
图5是本发明的实施例中正常小鼠喂食益生菌后葡萄糖耐受实验后的血糖变化图;
图6是本发明的实施例中正常小鼠喂食益生菌后胰岛素敏感实验后的血糖变化图;
图7是本发明的实施例中模型小鼠喂食益生菌后胰岛素敏感实验后的血糖变化图。
具体实施方式
为了使本发明实现的技术手段与功效易于明白了解,以下结合实施例及附图对本发明作具体阐述。
本发明的一株能有效缓解糖尿病的植物乳杆菌(Lactobacillus plantarum)AR113菌株,已在2017年3月22日保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为CGMCC No.13909。
利用植物乳杆菌AR113菌株制备用于缓解糖尿病的制品中的应用。
本发明中的制品可以是药品、保健品或食品饮品。较佳的食品饮品可为在乳酸菌饮品、酸奶、发酵豆制品、菌粉或奶粉中加入有效量的植物乳杆菌AR113而制成的产品。
实施例:
(1)培养基的制备
MRS液体培养基:蛋白胨10g、酵母膏5g、柠檬酸二胺2g、牛肉膏10g、葡萄糖20g、Tween-801mL、乙酸钠5g、磷酸氢二钾2g、硫酸镁0.58g、硫酸锰0.25g、琼脂粉15g、蒸溜水1000mL。
MRS固体培养基:在MRS液体培养基中加入15g琼脂,加1000mL蒸馏水后灭菌备用。
(2)益生菌的培养
在MRS液体培养基中培养益生菌菌株至第二代,离心并用灭菌的蒸馏水洗涤两次并重悬,调节菌液浓度为2×109备用。
(3)大鼠的喂养及样本采集
喂养:购买7周龄的SD大鼠,适应1周,随机分成模型组和正常组,模型组喂养高脂饲料,正常组喂养普通饲料。在第7周结束时进行造模,注射STZ(25mg/kg),72h后血糖>=11.1mmol L–1造模成功,各组随机分为7组,(正常组,模型组,药组,正常113组,正常495组,模型113组,模型495组)。灌胃8周。饲养室内12h/12h昼夜明暗交替,室内温度保持在18-22℃,相对湿度保持在50-60%。定时补给饲料,饮用水,更换垫料,保证实验大鼠的正常饮食以及干燥卫生的生活环境。
体内动物实验,利用动物模型评价体外α葡萄糖苷酶抑制率强的菌株AR113和能力弱的菌株AR495分别在体内缓解糖尿病的效果。
选用7周龄的SD大鼠,适应性喂养1周后,分为正常组和模型组,模型组高脂喂养6周,正常组普通饲料。第7周末注射STZ造模,72h后空腹血糖高于11.1mmol/L即3造模成功。随后将其分成7大组(模型组、正常组、药物组、模型AR113组、模型495组、正常AR113组、正常AR495组),每组10只。灌胃8周,剂量为109CFU/ml,正常组和模型组灌胃无菌水10ml/kg。每周同一时间测定体重,空腹血糖。第16周结束断颈处死大鼠,收集血清、肝脏、肾、胰腺、结肠、脂肪等组织,分别放于4%多聚甲醛和-80℃的冰箱中保存。
(4)基本指标的测定:包括血脂水平(TC、TG、HDL-C、LDL-C)、肝糖原、胰岛素、胰高血糖素、糖化血红蛋白(HbA1c)。
(5)结果分析
如图1所示,注射STZ后,模型组各组体重都明显的下降,之后除了模型组之外,益生菌组和药物组体重有所回升,到实验结束,各组体重都趋于稳定,益生菌及二甲双胍对于大鼠体重没有明显的改善作用。
如图2和图3所示,各个正常组血糖值都在6mmol/L上下浮动,没有差异。各个模型组经过8周到灌胃后,模型组AR113和二甲双胍组血糖明显下降,相对于模型组具有显著性。模型组血糖基本没有变化,AR495血糖值没有得到改善,基本保持稳定,表明AR113和二甲双胍起到了降低血糖的作用,需进一步探究降糖的机制。
如图4和图5所示,葡萄糖耐受实验(OGTT)是测定的主要是全身胰岛素的分泌,实验结果植物乳杆菌AR113对于全身胰岛素分泌的改善作用有一定的作用,但是不明显。需要进行ITT实验进一步确定是否植物乳杆菌AR113起到改善胰岛素抵抗的作用。
ITT是胰岛素敏感实验,从图6和图7中可以看出大鼠空腹注射胰岛素后,正常组,正常AR113,正常495组,血糖下降很明显,最后达到2.6mmol/L左右。相对于模型组和模型AR495,模型组AR113和药组血糖下降很明显,也就表明了植物乳杆菌AR113对于缓解胰岛素抵抗有一定的作用。
实施例的作用与效果
上述实施例中通过体内实验即对对大鼠体重的观察、血糖的测定以及改善胰岛素抵抗的实验,得知本发明的植物乳杆菌AR113能够降低血糖,并对缓解胰岛素抵抗具有一定的作用。
此外,本发明的植物乳杆菌AR113是安全、无毒副作用的益生菌,能够有效缓解甚至治疗糖尿病,即降低血糖的同时还能改善胰岛素抵抗,另外,还具有可以长期实用的安全性,且成本低、安全性高、可靠性高,能够用来制备用于缓解甚至治疗糖尿病的药品、保健品或食品饮品。
上述实施方式为本发明的优选案例,并不用来限制本发明的保护范围。
Claims (2)
1.一株能有效缓解糖尿病的植物乳杆菌(Lactobacillusplantarum)AR113菌株,其特征在于:所述植物乳杆菌AR113菌株已在2017年3月22日保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为CGMCCNo.13909。
2.利用权利要求1所述的植物乳杆菌AR113菌株制备用于缓解糖尿病的制品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010223696.XA CN111304134B (zh) | 2020-03-26 | 2020-03-26 | 一株能有效缓解糖尿病的植物乳杆菌 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010223696.XA CN111304134B (zh) | 2020-03-26 | 2020-03-26 | 一株能有效缓解糖尿病的植物乳杆菌 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111304134A true CN111304134A (zh) | 2020-06-19 |
CN111304134B CN111304134B (zh) | 2023-03-31 |
Family
ID=71153630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010223696.XA Active CN111304134B (zh) | 2020-03-26 | 2020-03-26 | 一株能有效缓解糖尿病的植物乳杆菌 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111304134B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112656819A (zh) * | 2020-12-18 | 2021-04-16 | 中国农业科学院麻类研究所 | 植物乳杆菌在促进肝脏再生方面的应用 |
CN114621896A (zh) * | 2022-03-23 | 2022-06-14 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | 一株具有降糖降脂功能的植物乳杆菌84-3及其应用 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150250835A1 (en) * | 2014-03-07 | 2015-09-10 | Genmont Biotech Inc. | Composition and method of lactobacillus reuteri gmnl-89 in treating type 2 diabetes |
CN106520819A (zh) * | 2016-09-13 | 2017-03-22 | 上海理工大学 | 一种乳酸菌双基因表达盒及其构建方法和应用 |
CN107502575A (zh) * | 2017-09-20 | 2017-12-22 | 中国农业科学院农产品加工研究所 | 一株具有α‑葡萄糖苷酶高抑制活性的植物乳杆菌 |
CN109810912A (zh) * | 2017-11-21 | 2019-05-28 | 华大精准营养(深圳)科技有限公司 | 一株植物乳杆菌lh-511及其应用 |
CN110387330A (zh) * | 2019-07-17 | 2019-10-29 | 上海理工大学 | 利用复合保护剂提高植物乳杆菌存活率的冷冻干燥方法 |
CN110423710A (zh) * | 2019-07-17 | 2019-11-08 | 上海理工大学 | 一种提高植物乳杆菌存活率的冷冻干燥方法 |
CN110468050A (zh) * | 2019-07-17 | 2019-11-19 | 上海理工大学 | 一种利用多糖提高植物乳杆菌存活率的冷冻干燥方法 |
CN111011866A (zh) * | 2019-12-12 | 2020-04-17 | 上海理工大学 | 益生元在肠道环境中促进植物乳杆菌生长的应用 |
CN111394276A (zh) * | 2020-03-02 | 2020-07-10 | 上海理工大学 | 一种对脑卒中具有保护作用的植物乳杆菌 |
-
2020
- 2020-03-26 CN CN202010223696.XA patent/CN111304134B/zh active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150250835A1 (en) * | 2014-03-07 | 2015-09-10 | Genmont Biotech Inc. | Composition and method of lactobacillus reuteri gmnl-89 in treating type 2 diabetes |
CN106520819A (zh) * | 2016-09-13 | 2017-03-22 | 上海理工大学 | 一种乳酸菌双基因表达盒及其构建方法和应用 |
CN107502575A (zh) * | 2017-09-20 | 2017-12-22 | 中国农业科学院农产品加工研究所 | 一株具有α‑葡萄糖苷酶高抑制活性的植物乳杆菌 |
CN109810912A (zh) * | 2017-11-21 | 2019-05-28 | 华大精准营养(深圳)科技有限公司 | 一株植物乳杆菌lh-511及其应用 |
CN110387330A (zh) * | 2019-07-17 | 2019-10-29 | 上海理工大学 | 利用复合保护剂提高植物乳杆菌存活率的冷冻干燥方法 |
CN110423710A (zh) * | 2019-07-17 | 2019-11-08 | 上海理工大学 | 一种提高植物乳杆菌存活率的冷冻干燥方法 |
CN110468050A (zh) * | 2019-07-17 | 2019-11-19 | 上海理工大学 | 一种利用多糖提高植物乳杆菌存活率的冷冻干燥方法 |
CN111011866A (zh) * | 2019-12-12 | 2020-04-17 | 上海理工大学 | 益生元在肠道环境中促进植物乳杆菌生长的应用 |
CN111394276A (zh) * | 2020-03-02 | 2020-07-10 | 上海理工大学 | 一种对脑卒中具有保护作用的植物乳杆菌 |
Non-Patent Citations (1)
Title |
---|
李向菲: "产孢外多糖乳酸菌对2型糖尿病的干预及其机制研究", 《中国优秀博硕士学位论文全文数据库(博士) 医药卫生科技辑》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112656819A (zh) * | 2020-12-18 | 2021-04-16 | 中国农业科学院麻类研究所 | 植物乳杆菌在促进肝脏再生方面的应用 |
CN112656819B (zh) * | 2020-12-18 | 2023-01-24 | 中国农业科学院麻类研究所 | 植物乳杆菌在促进肝脏再生方面的应用 |
CN114621896A (zh) * | 2022-03-23 | 2022-06-14 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | 一株具有降糖降脂功能的植物乳杆菌84-3及其应用 |
CN114621896B (zh) * | 2022-03-23 | 2022-10-11 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | 一株具有降糖降脂功能的植物乳杆菌84-3及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN111304134B (zh) | 2023-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111346114A (zh) | 罗伊氏乳杆菌的用途 | |
US20150037286A1 (en) | Use of roseburia in the prevention and treatment for obesity related diseases | |
JP6684966B2 (ja) | 新規なラクトバチルス・サケイ及びそれを含む組成物 | |
CN106176833A (zh) | 一种防治糖尿病并控制体重的复合益生菌液及其制备方法 | |
CN102935092A (zh) | 新颖乳杆菌及其组合物和在制备改善糖尿病及其并发症药物中的应用 | |
CN113308421B (zh) | 一种植物乳杆菌bufx及其在代谢综合征中的应用 | |
CN109221519A (zh) | 一种降血糖用低聚糖益生菌固体饮料及其制备方法 | |
EP3202892A1 (en) | Uses of bacteroides in treatment or prevention of obesity-related diseases | |
CN111304134B (zh) | 一株能有效缓解糖尿病的植物乳杆菌 | |
CN110558463A (zh) | 一种预防和控制糖尿病的益生菌发酵饮料及其制备方法 | |
CN113425762B (zh) | 一种桑葚发酵产物及其制备方法和应用 | |
CN104430849A (zh) | 用于抗糖尿病的多菌发酵脱脂驼乳及其生产方法 | |
US10350248B2 (en) | Uses of bacteroides in treatment or prevention of obesity and obesity-related diseases | |
CN116855413B (zh) | 利用鼠李糖乳杆菌YSs069制备调节人体微生态平衡的生物活性物质及其应用 | |
CN114540257B (zh) | 一种卷曲乳杆菌iob901及其在降糖降脂方面的应用 | |
CN113384600B (zh) | 一种灭活乳酸菌复合物在制备治疗和/或预防糖尿病产品中的应用 | |
CN110074392A (zh) | 一种解酒保肝养胃护肠组合物及其制备方法 | |
CN108653298A (zh) | 单糖组合物、药物制剂及其应用 | |
CN113116941A (zh) | 一种可缓解2型糖尿病的益生菌、益生元复合制剂及其制备方法 | |
CN109674060B (zh) | 一种具有辅助缓解二型糖尿病功能的益生菌膳食补充剂及其应用 | |
CN111345345A (zh) | 戊糖片球菌的用途 | |
CN115581302B (zh) | 一种减脂组合物、减脂产品及其用途 | |
CN117050914B (zh) | 一种嗜黏蛋白阿克曼氏菌及其在改善glp-1分泌量中的应用 | |
CN113274478B (zh) | 一种治疗痛风的中药发酵制剂及其制备方法 | |
CN116875500B (zh) | 利用罗伊氏乳杆菌YSs207制备调节人体微生态平衡的生物活性物质及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20200619 Assignee: Hubei Junyao health drink Co.,Ltd. Assignor: University of Shanghai for Science and Technology Contract record no.: X2024310000005 Denomination of invention: A Lactobacillus plantarum strain that can effectively alleviate diabetes Granted publication date: 20230331 License type: Exclusive License Record date: 20240108 |